Showing results (91-100 of 243) with videos related to
Sort By:
Pageof 25
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|May 11, 2010
Basic and clinical studies on functional RNA molecules for advanced medical technologiesToshihiro Takizawa, Akihiko Gemma, Kumiko Ui-Tei, et al.Lung Cancer (Amsterdam, Netherlands)|May 25, 2010
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumoniasYuji Minegishi, Junko Sudoh, Hideaki Kuribayasi, et al.Thoracic Cancer|May 3, 2021
Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cellsKakeru Hisakane, Masahiro Seike, Teppei Sugano, et al.BMC Pulmonary Medicine|January 8, 2025
Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II studyMasaru Matsumoto, Yuji Minegishi, Katsuyuki Higa, et al.Translational Lung Cancer Research|October 19, 2023
Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancerHirokazu Iso, Kakeru Hisakane, Erika Mikami, et al.Oncology Reports|April 26, 2017
AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifierMasahiro Seike, Cheol-Hong Kim, Fenfei Zou, et al.Journal of Thoracic Disease|August 3, 2019
Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitorsYasuhiro Kato, Yukio Hosomi, Kageaki Watanabe, et al.International Journal of Clinical Oncology|March 4, 2021
Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutationsYasuhiro Kato, Gou Yamamoto, Yasutaka Watanabe, et al.Anticancer Research|January 29, 2018
Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung CancerYasuhiro Kato, Jumpei Kashima, Kageaki Watanabe, et al.International Journal of Oncology|July 4, 2012
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cellsMengru Cao, Masahiro Seike, Chie Soeno, et al.Pageof 25